This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignees: Dana-Farber-Cancer Institute Inc., The Broad Institute, Inc., The General Hospital Corporation. Active years: 2020.
Company Filing History:
1 out of 1,264 
1 out of 480 
1 out of 3,068 
Years Active: 2020
Title: Pavan Bachireddy: Innovator in Cancer Immunotherapy
Introduction
Pavan Bachireddy is a notable inventor based in Boston, MA (US). He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative work on neoantigens. His research focuses on developing pharmaceutical compositions that can enhance the immune response against tumors.
Latest Patents
Pavan Bachireddy holds 1 patent related to shared neoantigens. This patent discloses a pharmaceutical composition comprising a plurality of neoantigenic peptides and a pharmaceutically acceptable carrier. Each neoantigenic peptide includes a tumor-specific neoepitope capable of binding to an HLA protein in a subject. The composition is designed to include neoantigenic peptides that comprise tumor-specific mutations present in at least 1% of subjects suffering from cancer. Additionally, it features neoantigenic peptides that bind to HLA proteins present in at least 5% of subjects in the population. Importantly, the composition also includes at least one neoantigenic peptide capable of eliciting an immune response against a tumor present in at least 5% of the subjects.
Career Highlights
Throughout his career, Pavan has worked with prestigious organizations such as the Broad Institute and Dana-Farber Cancer Institute. His experience in these institutions has allowed him to collaborate with leading experts in the field of cancer research and immunotherapy.
Collaborations
Pavan has collaborated with notable colleagues, including Michael Steven Rooney and Edward F. Fritsch. These partnerships have contributed to the advancement of his research and the development of innovative therapeutic strategies.
Conclusion
Pavan Bachireddy is a pioneering inventor whose work in cancer immunotherapy is making a significant impact. His innovative approach to neoantigens holds promise for improving treatment options for cancer patients.